{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-22-000046","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.145043+00:00","generated_at":"2026-06-22T08:59:05.868648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena Q3 2022 net loss $45.8M vs income $109.2M y/y; cash $497M; cuts FY22 net cash burn guidance to $108-120M","bullets":["Net loss $45.8M ($0.97 per share) vs net income $109.2M ($2.13 diluted EPS) in Q3 2021.","Total revenue $1.5M vs $139.2M y/y, primarily due to prior year BMS and Novo Nordisk milestones.","Cash and restricted cash $497.0M; no debt; shares outstanding ~48.4M as of Oct 26.","Updated FY2022 net cash burn guidance $108-120M (down from $120-132M); year-end cash ~$522M.","R&D expenses $39.9M in Q3 2022 vs $18.0M y/y, driven by manufacturing and clinical costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-22-000046","json":"https://secwatch.observer/filing/0001559053-22-000046.json","markdown":"https://secwatch.observer/filing/0001559053-22-000046.md","text":"https://secwatch.observer/filing/0001559053-22-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/0001559053-22-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/prta-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:59:05.868648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34825443ef467c1fea589a24a47b11c4096d93e0","claim":"PROTHENA CORP PUBLIC LTD CO reported third quarter ended September 30, 2022 results: revenue $1.5 million, net income net loss of $45.8 million, EPS $0.97.","evidence_excerpt":"For the third quarter and first nine months of 2022, Prothena reported a net loss of $45.8 million and $123.3 million, respectively, as compared to a net income o f $109.2 million and $100.2 million for the third quarter and first nine months of 2021, respectively. Net loss per share for the third quarter of 2022 and first nine months of 2022 was $0.97, and $2.63, respectively, a s compared to net income per share on a diluted basis of $2.13 and $2.12 f or the third quarter and first nine months of 2021, respectively. Prothena reported total revenue of $1.5 million and $4.0 million for the third quarter and first nine months of 2022, respectively, primarily from collaboration revenue from BMS.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000046/0001559053-22-000046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$1.5 million"},{"label":"Net income","value":"net loss of $45.8 million"},{"label":"EPS","value":"$0.97"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}